{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:37:42Z","timestamp":1791819462672,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Institute","award":["R21 CA161889-01"],"award-info":[{"award-number":["R21 CA161889-01"]}]},{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["K24CA201543-01"],"award-info":[{"award-number":["K24CA201543-01"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220631"],"award-info":[{"award-number":["RP220631"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00280-023-04543-6","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T10:02:01Z","timestamp":1684404121000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies"],"prefix":"10.1007","volume":"92","author":[{"given":"Alexis C.","family":"Boulter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Pogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min H.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwangeui","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Patrick","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7812-6741","authenticated-orcid":false,"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"issue":"25","key":"4543_CR1","doi-asserted-by":"publisher","first-page":"15371","DOI":"10.1074\/jbc.R115.653204","volume":"290","author":"MM Siddique","year":"2015","unstructured":"Siddique MM, Li Y, Chaurasia B, Kaddai VA, Summers SA (2015) Dihydroceramides: from bit players to lead actors. J Biol Chem 290(25):15371\u201315379","journal-title":"J Biol Chem"},{"issue":"1","key":"4543_CR2","doi-asserted-by":"publisher","first-page":"E122","DOI":"10.1152\/ajpendo.00330.2020","volume":"320","author":"F Lachkar","year":"2021","unstructured":"Lachkar F, Ferr\u00e9 P, Foufelle F, Papaioannou A (2021) Dihydroceramides: their emerging physiological roles and functions in cancer and metabolic diseases. Am J Physiol Endocrinol Metab 320(1):E122-e130","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3\u20134","key":"4543_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3109\/10428199709114166","volume":"25","author":"LN Chan","year":"1997","unstructured":"Chan LN, Zhang S, Shao J, Waikel R, Thompson EA, Chan TS (1997) N-(4-hydroxyphenyl) retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Leuk Lymphoma 25(3\u20134):271\u2013280","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4543_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.2910590322","volume":"59","author":"A Di Vinci","year":"1994","unstructured":"Di Vinci A, Geido E, Infusini E, Giaretti W (1994) Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. Int J Cancer 59(3):422\u2013426","journal-title":"Int J Cancer"},{"issue":"2","key":"4543_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s002800050875","volume":"43","author":"GP Kalemkerian","year":"1999","unstructured":"Kalemkerian GP, Ou X (1999) Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines. Cancer Chemother Pharmacol 43(2):145\u2013150","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4543_CR6","first-page":"1056","volume":"56","author":"SM Kazmi","year":"1996","unstructured":"Kazmi SM, Plante RK, Visconti V, Lau CY (1996) Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res 56(5):1056\u20131062","journal-title":"Cancer Res"},{"issue":"8","key":"4543_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/90.8.597","volume":"90","author":"AL Sabichi","year":"1998","unstructured":"Sabichi AL, Hendricks DT, Bober MA, Birrer MJ (1998) Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 90(8):597\u2013605","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"4543_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D","volume":"65","author":"R Supino","year":"1996","unstructured":"Supino R, Crosti M, Clerici M et al (1996) Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 65(4):491\u2013497","journal-title":"Int J Cancer"},{"issue":"15","key":"4543_CR9","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1158\/0008-5472.CAN-04-0377","volume":"64","author":"S Batra","year":"2004","unstructured":"Batra S, Reynolds CP, Maurer BJ (2004) Fenretinide cytotoxicity for Ewing\u2019s sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 64(15):5415\u20135424","journal-title":"Cancer Res"},{"issue":"5","key":"4543_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/carcin\/18.5.943","volume":"18","author":"D Delia","year":"1997","unstructured":"Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA (1997) Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 18(5):943\u2013948","journal-title":"Carcinogenesis"},{"issue":"10","key":"4543_CR11","first-page":"2493","volume":"59","author":"SY Sun","year":"1999","unstructured":"Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R (1999) Mediation of N-(4-hydoxyphenyl) retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 59(10):2493\u20132498","journal-title":"Cancer Res"},{"issue":"46","key":"4543_CR12","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1038\/sj.onc.1203024","volume":"18","author":"S Suzuki","year":"1999","unstructured":"Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK, Lotan R (1999) Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. Oncogene 18(46):6380\u20136387","journal-title":"Oncogene"},{"issue":"23","key":"4543_CR13","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/jnci\/92.23.1897","volume":"92","author":"BJ Maurer","year":"2000","unstructured":"Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP (2000) Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92(23):1897\u20131909","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"4543_CR14","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/91.13.1138","volume":"91","author":"BJ Maurer","year":"1999","unstructured":"Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP (1999) Increase of ceramide and induction of mixed apoptosis\/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91(13):1138\u20131146","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4543_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1194\/jlr.R031278","volume":"54","author":"MM Young","year":"2013","unstructured":"Young MM, Kester M, Wang HG (2013) Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J Lipid Res 54(1):5\u201319","journal-title":"J Lipid Res"},{"issue":"21","key":"4543_CR16","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1158\/1078-0432.CCR-11-0995","volume":"17","author":"JG Villablanca","year":"2011","unstructured":"Villablanca JG, London WB, Naranjo A et al (2011) Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR\/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the children\u2019s oncology group. Clin Cancer Res 17(21):6858\u20136866","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4543_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41419-019-1775-y","volume":"10","author":"I Orienti","year":"2019","unstructured":"Orienti I, Francescangeli F, De Angelis ML et al (2019) A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death Dis 10(7):529","journal-title":"Cell Death Dis"},{"issue":"16","key":"4543_CR18","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-17-0234","volume":"23","author":"AM Mohrbacher","year":"2017","unstructured":"Mohrbacher AM, Yang AS, Groshen S et al (2017) Phase I study of fenretinide delivered intravenously in patients with relapsed or refractory hematologic malignancies: a california cancer consortium trial. Clin Cancer Res 23(16):4550\u20134555","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4543_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00280-020-04224-8","volume":"87","author":"JS Thomas","year":"2021","unstructured":"Thomas JS, El-Khoueiry AB, Maurer BJ et al (2021) A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol 87(4):525\u2013532","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"4543_CR20","first-page":"5102","volume":"61","author":"H Wang","year":"2001","unstructured":"Wang H, Maurer BJ, Reynolds CP, Cabot MC (2001) N-(4-hydroxyphenyl) retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 61(13):5102\u20135105","journal-title":"Cancer Res"},{"issue":"8","key":"4543_CR21","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-10-2323","volume":"17","author":"MA Dickson","year":"2011","unstructured":"Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK (2011) A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res 17(8):2484\u20132492","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4543_CR22","first-page":"537","volume":"3","author":"GK Schwartz","year":"1997","unstructured":"Schwartz GK, Ward D, Saltz L et al (1997) A pilot clinical\/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 3(4):537\u2013543","journal-title":"Clin Cancer Res"},{"key":"4543_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/1756-0500-7-256","volume":"7","author":"MH Kang","year":"2014","unstructured":"Kang MH, Villablanca JG, Glade Bender JL et al (2014) Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches To Neuroblastoma (NANT) Phase I study. BMC Res Notes 7:256","journal-title":"BMC Res Notes"},{"issue":"15","key":"4543_CR24","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.ejca.2014.06.023","volume":"50","author":"D Bhojwani","year":"2014","unstructured":"Bhojwani D, Darbandi R, Pei D et al (2014) Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer 50(15):2685\u20132694","journal-title":"Eur J Cancer"},{"issue":"1","key":"4543_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41421-020-00233-2","volume":"7","author":"C Dias","year":"2021","unstructured":"Dias C, Nylandsted J (2021) Plasma membrane integrity in health and disease: significance and therapeutic potential. Cell Discov 7(1):4","journal-title":"Cell Discov"},{"key":"4543_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jchromb.2019.02.023","volume":"1112","author":"HE Cho","year":"2019","unstructured":"Cho HE, Maurer BJ, Reynolds CP, Kang MH (2019) Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 1112:16\u201323","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4543_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpba.2016.09.046","volume":"132","author":"HE Cho","year":"2017","unstructured":"Cho HE, Min HK (2017) Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal 132:117\u2013124","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"4543_CR28","first-page":"507","volume":"3","author":"R Torrisi","year":"1994","unstructured":"Torrisi R, Parodi S, Fontana V et al (1994) Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients. Cancer Epidemiol Biomarkers Prev 3(6):507\u2013510","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4543_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/OARRR.S245662","volume":"12","author":"N Atik","year":"2020","unstructured":"Atik N, Hayati RU, Hamijoyo L (2020) Correlation between steroid therapy and lipid profile in systemic lupus erythematosus patients. Open Access Rheumatol 12:41\u201346","journal-title":"Open Access Rheumatol"},{"key":"4543_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104793","volume":"156","author":"E Jozefczuk","year":"2020","unstructured":"Jozefczuk E, Guzik TJ, Siedlinski M (2020) Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol Res 156:104793","journal-title":"Pharmacol Res"},{"issue":"1","key":"4543_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.atherosclerosis.2015.03.020","volume":"240","author":"F Pot\u00ec","year":"2015","unstructured":"Pot\u00ec F, Ceglarek U, Burkhardt R, Simoni M, Nofer JR (2015) SKI-II\u2013a sphingosine kinase 1 inhibitor\u2013exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-\/-) mice on high cholesterol diet. Atherosclerosis 240(1):212\u2013215","journal-title":"Atherosclerosis"},{"issue":"7","key":"4543_CR32","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.2741\/4458","volume":"21","author":"N Li","year":"2016","unstructured":"Li N, Zhang F (2016) Implication of sphingosin-1-phosphate in cardiovascular regulation. Front Biosci (Landmark Ed) 21(7):1296\u20131313","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"4","key":"4543_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00280-022-04461-z","volume":"90","author":"C Massard","year":"2022","unstructured":"Massard C, Cassier PA, Azaro A et al (2022) A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol 90(4):335\u2013344","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4543_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","volume":"91","author":"R Kim","year":"2023","unstructured":"Kim R, Leal AD, Parikh A et al (2023) A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol 91(4):291\u2013300","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4543_CR35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12885-021-08242-4","volume":"21","author":"KC Kelley","year":"2021","unstructured":"Kelley KC, Grossman KF, Brittain-Blankenship M et al (2021) A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer 21(1):510","journal-title":"BMC Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04543-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T02:01:56Z","timestamp":1688695316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04543-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4543"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04543-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"9 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interests directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}